Grantvello Find funders

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Open

National Institutes of Health · Opportunity number PAR-25-070

PostedNov 18, 2024
Closing dateJan 7, 2027
Award ceilingNot listed
Expected awardsNot listed
From Grants.gov

Eligibility

Nonprofits are listed as eligible applicants.

  • Independent school districts
  • Special district governments
  • Public and state controlled institutions of higher education
  • Public housing authorities/Indian housing authorities
  • Small businesses
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Native American tribal governments (Federally recognized)
  • For profit organizations other than small businesses
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • City or township governments
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Private institutions of higher education
  • County governments
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • State governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Description

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Funding

Total program fundingNot listed
Award floorNot listed
Award ceilingNot listed
CategoryEducation, Health
Assistance listing93.393,

Official sources

Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.